ONCOMATRYX, a biopharmaceutical company developing novel ADCs against the tumor microenvironment, announced it has raised €25 million to fund Phase Ib-II clinical trials of OMTX705, a first-in-class ADC targeting FAP. This funding round was led by the company’s existing investors and included a €10 million strategic investment from Centro para el Desarrollo Tecnológico y la Innovación. And this endorsement highlights the confidence in ONCOMATRYX pioneering ADCs to treat metastatic solid tumors.
Oncomatryx developed a proprietary Antibody-Drug Conjugates platform that targets Cancer-Associated Fibroblasts in the microenvironment of metastatic solid tumors. And Oncomatryx pioneers ADCs against immunosuppressive CAFs are developed in collaboration with universities, hospitals and research centers in USA and Europe.
The Phase I clinical results of OMTX705, a novel ADC targeting Fibroblast Activation Protein in the Cancer-Associated Fibroblasts, will be presented at major Oncology conferences along 2025.
KEY QUOTE:
“We are thrilled to count on the continued support of our existing investors and welcome CDTI through Innvierte, an investment program of CDTI. This funding validates our clinical progress and equips us to execute on critical milestones and deliver transformative therapies to patients.”
– Dr. Laureano Simon, CEO of ONCOMATRYX
